Project description DEENESFRITPL Human genome pathogenic micropeptides Recent studies have discovered a striking number of regions of the genome that are capable of being transcribed and translated into short polypeptides. These micropeptides comprise less than 100 amino acids, and more than 160 000 different micropeptides have been cataloged within human tissues so far. The current hypothesis is that these genome products might participate in numerous physiological processes, yet the function of only a few micropeptides has been clarified. The EU-funded GENOMEPEP project aims to identify particular micropeptides participating in the pathogenesis of cardiovascular diseases by analysing the genetic variation within the micropeptidome-encoding genome in correlation to existing common cardiovascular phenotypes in the population. Show the project objective Hide the project objective Objective The human genome is over 3 billion nucleotides long, yet only 1,5% of it codes for proteins. In recent years, a striking number of regions of the genome have been discovered to be capable of being transcribed and translated into short polypeptides. These micropeptides comprise of less than 100 amino acids and to date, more than 160 000 different micropeptides have been catalogued within human tissues. These protein products are hypothesized to participate in numerous molecular, cellular and physiological processes, yet the function of but a few micropeptides has been identified. Subsequently, due to its largely unknown functionality, the micropeptidome is commonly overlooked during genomic studies.Due to increasing life expectancy and detrimental lifestyle habits, the European population can be considered to be a high-risk population for cardiovascular diseases, which cause millions of deaths per annum, while taking a tremendous financial toll on the regional economy. GENOMEPEP aims to pinpoint novel micropeptides participating in the pathogenesis of cardiovascular diseases by investigating the genetic variation within the micropeptidome-encoding genome in correlation to existing common cardiovascular phenotypes in population. This will be achieved by establishing a computational analysis pipeline based on biometric, genotype and health records data available within the Estonian and Finnish biobanks. The identification of novel pathogenic genes and the development of guidelines to investigate the micropeptidome would assist in the advancement of research, diagnostic medicine and pharmacology both in public and private sectors.The results of GENOMEPEP will address the CVD research aspect highlighted in “Societal Challenge 1” work program of Horizon 2020, as well as improve other research priorities set by Horizon 2020, e.g. the progression of personalized medicine and support the decrease of economic burden by healthcare. Fields of science natural sciencesbiological sciencesbiochemistrybiomoleculesproteinsmedical and health sciencesclinical medicinecardiologycardiovascular diseasesmedical and health scienceshealth sciencespersonalized medicinenatural sciencesbiological sciencesgeneticsgenomesmedical and health sciencesbasic medicinepharmacology and pharmacy Keywords Cardiovascular diseases Genome-wide association studies Phenome-wide association studies Micropeptides small Open Reading Frames (sORFs) Bioinformatics Non-coding genome Metabolomics Programme(s) H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions Main Programme H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility Topic(s) MSCA-IF-2019 - Individual Fellowships Call for proposal H2020-MSCA-IF-2019 See other projects for this call Funding Scheme MSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF) Coordinator TARTU ULIKOOL Net EU contribution € 213 289,92 Address Ulikooli 18 51005 Tartu Estonia See on map Region Eesti Eesti Lõuna-Eesti Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 0,00
